Physician profile
Antonio Capone
NPI 1760411664
$20,000.88
in general payments reported to CMS, 2019-2025
21 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $83.79 · 2021: $801 · 2022: $709 · 2023: $3,001 · 2024: $14K · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $3,912 · Food and Beverage: $3,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,317.00 |
| Travel and Lodging | $3,911.51 |
| Food and Beverage | $3,255.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $12,411.84 | 2022-2024 | Syfovre |
| Carl Zeiss Meditec USA, INC. | $2,561.18 | 2023 | Clarus, Cirrus Hd-Oct, Iolmaster 700 |
| Genentech, INC. | $856.97 | 2019 | |
| Allergan, INC. | $842.54 | 2019-2021 | |
| Genentech USA, INC. | $826.38 | 2021-2025 | Vabysmo |
| Alimera Sciences, INC. | $776.02 | 2020-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $521.62 | 2023-2025 | Eylea Hd |
| Astellas Pharma US INC | $336.84 | 2023-2025 | Izervay |
| Janssen Pharmaceuticals, INC | $156.04 | 2023 | |
| Alcon Vision LLC | $150.00 | 2022 | |
| Abbvie INC. | $125.88 | 2023-2025 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $124.99 | 2024 | Eylea Hd |
| Astellas Pharma Global Development | $107.10 | 2025 | Izervay |
| Asd Specialty Healthcare, LLC | $89.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.80 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $26.45 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.98 | 2025 | Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.31 | 2021 | |
| Eyepoint US, INC. | $13.25 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Capone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.